Use

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Retrieved on: 
Wednesday, March 13, 2024
CD4, PDSB, Infection, Patent, Influenza, Research, Virus, Biotechnology, Antibody, Intellectual property, Use, Viral, Vaccine

PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell-activating platforms, today announced the publication of preclinical research and a patent granted by the United States Patent and Trademark Office (USPTO) that strengthen the foundation of the Company’s infectious disease vaccine platform Infectimune®.

Key Points: 
  • The research concluded that Infectimune® is a leading candidate for use in the next generation of preventive vaccines that may provide more effective and broader protection than current vaccines allow.
  • Infectimune® is being used in PDS0202, the Company’s universal influenza vaccine intended to provide broad protection against multiple flu strains.
  • The patent protects compositions containing the Infectimune® platform and influenza antigens and methods of using the Infectimune® platform with pathogenic antigens generally.
  • “Possessing multiple layers of intellectual property for our assets is an important value driver for PDS Biotech and is a key component of our business strategy.”

HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes

Retrieved on: 
Tuesday, March 12, 2024
Diabetes, ARIC, HSCS, Cardiovascular disease, Algorithm, Learning, Risk, Intelligence, Patient, Atherosclerosis, HF, Death, Type 2 diabetes, Type, Use, T2DM, Cardiovascular Diabetology, Medicine, Medical device

Recent guidelines propose N-terminal pro-B-type natriuretic peptide (blood test for NT-proBNP protein marker) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes (T2DM) patients.

Key Points: 
  • Recent guidelines propose N-terminal pro-B-type natriuretic peptide (blood test for NT-proBNP protein marker) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes (T2DM) patients.
  • Accordingly, the study sought to evaluate whether an AI-ECG model based on MyoVista® wavECG™ features was superior to NT-proBNP, as well as a conventional screening tool—the Atherosclerosis Risk in Communities (ARIC) HF risk score, in SBHF screening among patients with T2DM.
  • This independent study provides evidence of the clinical and diagnostic capabilities of AI-ECG, and specifically our MyoVista wavECG technology, to potentially advance current standards of care for heart screening in diabetic patients.” said Andrew Simpson, Chief Executive Officer of HeartSciences.
  • “Globally cardiovascular disease accounts for approximately one-third of all annual deaths and AI-ECG is set to change medicine by providing the opportunity to detect heart disease earlier and more effectively, not only for diabetic patients, but also for a significant number of at-risk patients.

PyroGenesis Announces Accelerated Construction of Fumed Silica Reactor Project with Arrival of All Major Equipment

Retrieved on: 
Tuesday, March 12, 2024
Hydrogen, Adhesive, Silicon dioxide, Fumed silica, Agriculture, Safety, GHG, EBIDTA, Health, Ventilation, FRA, 0 A.D. (video game), HPQ, FSR, TPY, Pollution, Carbon, Silicon, TSX, Siloxane, CO2, Silicon tetrachloride, Confidentiality, News, AN, Use, Oxygen, Greenhouse, PCC, Cement

The Fumed Silica Reactor (FSR) technology project is being conducted in conjunction with HPQ Silica Polvere Inc. (“HPQ Polvere”), a wholly owned subsidiary of HPQ.

Key Points: 
  • The Fumed Silica Reactor (FSR) technology project is being conducted in conjunction with HPQ Silica Polvere Inc. (“HPQ Polvere”), a wholly owned subsidiary of HPQ.
  • With all major equipment now on site, the construction phase of the 50 tonnes per year (TPY) FSR pilot plant is accelerating.
  • The FSR converts quartz into fumed silica (also known as pyrogenic silica) in a single and eco-friendly step while eliminating the use of harmful chemicals generated by conventional methods.
  • Fumed silica sales accounted for almost 23% of the global specialty silica market at the end of 2021.

American Institutes for Research Experts to Present at the Annual Association for Education Finance & Policy Conference

Retrieved on: 
Tuesday, March 12, 2024
Education Ecosystem, Education, American Institutes for Research, COVID-19, Policy, Licensure, Effectiveness, Use, AIR, Tutoring

Arlington, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Experts from the American Institutes for Research (AIR) will explore a variety of topics at the annual Association for Education Finance & Policy (AEFP) conference , being held March 14–16 in Baltimore.

Key Points: 
  • Arlington, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Experts from the American Institutes for Research (AIR) will explore a variety of topics at the annual Association for Education Finance & Policy (AEFP) conference , being held March 14–16 in Baltimore.
  • This year’s conference theme is “Engaging The Education Ecosystem To Improve Research Relevance And Use,” and is designed for members to engage with one another around rigorous research that can inform education finance and policy decisions.
  • Attendees will present, discuss, and evaluate the latest research and data on education finance and policy from pre-K to postsecondary education.
  • All AIR presentations are available via the searchable AEFP conference program (search for American Institutes for Research).

Mastercard Announces New Cardholder Benefits to Enhance Health & Wellness, Travel and Lifestyle Rewards for Consumers, Small Businesses

Retrieved on: 
Thursday, April 4, 2024
Banking, Networks, Other Retail, Professional Services, Data Management, Payments, Consumer, Transportation, Technology, Food, Beverage, Travel, Retail, Other Consumer, Friends, Tax, Health, Running, Transport, Schedule, Engineering, Policy, Partnership, Business, Booking.com, Fraud, Standard, Privacy, IOS, Mastercard, EVP, Coffee, Insurance, Meditation, MoviePass, Drink, Use, Family, Movement, Work, Instacart, Credit card, Small business, Snack, Payment card

Lyft: Eligible World Elite Mastercard® consumer credit cardholders and World Elite Mastercard for Business® small business credit cardholders will receive 10% off all scheduled rides to the airport.

Key Points: 
  • Lyft: Eligible World Elite Mastercard® consumer credit cardholders and World Elite Mastercard for Business® small business credit cardholders will receive 10% off all scheduled rides to the airport.
  • In addition to Mastercard’s existing consumer Instacart cardholder benefit , Instacart Business is now added to the suite of benefits for small business owners.
  • Qualifying Mastercard cardholders will also get a $20 discount on their second qualifying monthly order after completing their first qualifying monthly order 9.
  • "The collaboration with Mastercard is a great opportunity to further enhance the travel experiences of Mastercard cardholders,” says Cintia O Tavella Gomez, Head of Partnerships at Booking.com.

PharmaJet Announces Scientific Advisory Boards and Presentation at World Vaccine Congress in Washington on April 1

Retrieved on: 
Monday, April 1, 2024
Oncology, Health, Medical Devices, Infectious Diseases, Health Technology, Pharmaceutical, Biotechnology, MSD, Research, Clinical research, Government, Congress, Global health, Policy, Cancer, University, Infection, Former, Injection, Emerita, SAB, Immune system, Therapy, Use, Multimedia, Vaccine, Chiron, Medical director

The Boards will provide strategic guidance and expertise to help PharmaJet advance its vision to better activate the immune system with its unique technology and accelerate its partnering strategy with vaccine and pharmaceutical companies.

Key Points: 
  • The Boards will provide strategic guidance and expertise to help PharmaJet advance its vision to better activate the immune system with its unique technology and accelerate its partnering strategy with vaccine and pharmaceutical companies.
  • View the full release here: https://www.businesswire.com/news/home/20240401778401/en/
    In the countries highlighted, PharmaJet has commercial and development partners for prophylactic vaccines for the prevention of infectious diseases as well as cancer treatments.
  • To date, more than 10 million vaccinations have been made and PharmaJet has over 80 global development partners.
  • To find out how this innovative technology can help your vaccine or therapeutic program, schedule a meeting with one of our company experts by clicking here .

Can-Fite Reports 2023 Financial Results and Clinical Update

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Human, Psoriasis, Exercise, ALT, Patent, BID, CANF, Patient, CEE, Journal, Policy, EMA, Security (finance), Inflammation, Cancer, Bank statement, European Medicines Agency, Pancreatic cancer, Annual report, Skin, The Annual Report, PASI, Safety, NASH, Use, Liver cancer, FDA, Food, DSM-IV codes, Pharmaceutical industry

(NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended December 31, 2023.

Key Points: 
  • (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended December 31, 2023.
  • EADV is a top ranked peer reviewed journal (impact factor 9.2) that publishes articles on clinical and basic science topics in dermatology.
  • Financial income (expense), net for the year ended December 31, 2023 aggregated $0.56 million compared to financial expense, net of $(0.07) for the year ended December 31, 2022.
  • The Company's consolidated financial results for the year ended December 31, 2023 are presented in accordance with US GAAP Reporting Standards.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, March 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Liver-Assessment Tool Hepatoscope® Cleared for Use in U.S. and Europe Just as First Medication for MASH* Gains FDA Approval

Retrieved on: 
Tuesday, March 26, 2024
Software, Research, General Health, Medical Devices, Technology, Healthcare Reform, Science, Other Technology, FDA, Other Science, Health, Public Policy, Government, Diagnosis, Scripps Center, School corporal punishment, CE, Liver disease, Disease, Associate, Physician, F2, Risk, Cirrhosis, Patient, Syndrome, F3, Triage, Tool, Death, MASH, Fibrosis, LSM, Use, Multimedia, Hepatocellular carcinoma, Liver, Food, Medical imaging

This is a timely and exciting development in the fight against metabolism-related liver disease, which is on the rise globally.

Key Points: 
  • This is a timely and exciting development in the fight against metabolism-related liver disease, which is on the rise globally.
  • The economic burden attributed to effects of MASLD in the U.S. exceeds $100 billion annually.
  • “Medication that can reverse some of the worst impacts of MASH will be a huge help to our patients.
  • Questions of access matter more than ever,” he concluded, “as patients stand to benefit from these newer, more effective forms of treatment.”

New Check List Helps Consumers Adopt a “Papertarian” Lifestyle in Time for Earth Day

Retrieved on: 
Thursday, March 21, 2024
Environment, Packaging, Manufacturing, Home Goods, Sustainability, Forest Products, Retail, Recycling, Natural Resources, Ice cream, Drink, Habit, Paper, Cosmetics, Use, Soap, Detergent, Earth Day

Helping consumers become papertarians is the goal of a new check list developed by the Paper and Packaging Board (P+PB).

Key Points: 
  • Helping consumers become papertarians is the goal of a new check list developed by the Paper and Packaging Board (P+PB).
  • In time for Earth Day 2024, the Papertarian Check List aims to help consumers build long-term, environmentally friendly habits.
  • “Earth Day has helped people embrace a mindset about how we can and should protect our planet.
  • “Everyone can be a papertarian!”
    The Papertarian Check List has tips showing how to work paper into all facets of everyday life—including shopping, working, living, and then recycling.